- Free worldwide shipping, tracked and insured
- Same day dispatch, customs handled
- Certificate of analysis for every batch
- Dual incretin receptor agonist research (GIP + GLP-1)
- Glucose-dependent insulin signaling pathway studies
- Body-composition and adiposity research
Overview
What is Tirzepatide?
Tirzepatide is a synthetic dual incretin receptor agonist that activates both the GIP and GLP-1 receptors from a single peptide. It is used as a research compound in studies of incretin signaling, glucose regulation, and body composition. Supplied for in-vitro and laboratory research use only.
Mechanism in research
How Tirzepatide is studied
In published research tirzepatide was characterized as a fatty-acid-modified peptide that binds and activates the GIP and GLP-1 receptors, two incretin pathways that converge on glucose-dependent insulin signaling. Discovery-stage pharmacology reported dual-agonist activity at both receptors, and subsequent controlled trials observed changes in body weight over the periods studied. Corresponding long-term mechanisms and outcomes in humans remain under investigation.
Reported targets & pathways
- GIP receptor
- GLP-1 receptor
- Incretin signaling axis
- Glucose-dependent insulin secretion
Reference data
Tirzepatide specifications
- Classification
- Synthetic dual GIP/GLP-1 receptor agonist peptide
- Development code
- LY3298176
- Molecular formula
- C225H348N48O68
- Molecular weight
- ~4813.5 g/mol (PubChem CID 166567236)
- Appearance
- White lyophilized powder
- Solubility
- Soluble in bacteriostatic water
- Molecular formula
- C225H348N48O68
- Molecular weight
- 4813.53 g/mol
- Purity
- 99.27%
- CAS number
- 2023788-19-2
- PubChem CID
- 166567236
Research applications
Where Tirzepatide is used in research
Areas of study described in the published literature. Listed for research reference only.
Incretin receptor pharmacology
Used to study parallel signaling at the GIP and GLP-1 receptors from a single dual-agonist peptide.
Glucose metabolism
Applied in research on glucose-dependent insulin secretion and metabolic regulation.
Body composition
Investigated in animal and clinical research models for effects on body weight and adiposity.
Comparative agonist studies
Explored alongside single-incretin agonists to compare dual- versus single-pathway activity.
Selected research
Published studies on Tirzepatide
Peer-reviewed references for further reading. Findings describe in-vitro and animal research; mechanisms and outcomes in humans are not established.
Molecular Metabolism · 2018
Reported the discovery and pharmacological characterization of LY3298176 (tirzepatide), a fatty-acid-modified peptide engineered as a dual agonist at the GIP and GLP-1 receptors.
New England Journal of Medicine · 2022
In the SURMOUNT-1 randomized trial, once-weekly tirzepatide was observed to produce substantial mean body-weight reductions over 72 weeks relative to placebo across the doses studied.
Comparison
Tirzepatide vs single-incretin agonists in research
| Tirzepatide | GLP-1 agonist | GIP agonist | |
|---|---|---|---|
| Receptor target | GIP + GLP-1 | GLP-1 receptor | GIP receptor |
| Class | Dual incretin agonist | Single incretin agonist | Single incretin agonist |
| Research focus | Combined incretin signaling | GLP-1 pathway | GIP pathway |
| Pathways engaged | Two | One | One |
Quality
Independently verified, batch by batch
Tested every batch
Every batch of Tirzepatide is independently analyzed by a third-party laboratory before it is released.
Independently verified
Identity and purity are confirmed by an independent third-party laboratory. This batch is verified to 99.27% purity.
Certificate of analysis
Every batch is independently tested with a certificate of analysis. We send a digital COA with your order.
Tirzepatide FAQ
Shipping Tirzepatide to India?
Free shipping, UPI payments, INR pricing, and same-day dispatch.
Related Products
Retatrutide
99.62% pureTriple agonist peptide targeting GLP-1, GIP, and glucagon receptors for metabolic and obesity research.
Tesamorelin
99.20% pureGHRH analogue that stimulates growth hormone release, researched for metabolic regulation and body composition studies.
MOTS-c
99.79% pureMitochondrial-derived peptide studied for metabolic regulation, insulin sensitivity, and cellular homeostasis.
CJC-1295 (No DAC)
99.60% pureHigh-purity (99.60%) CJC-1295 without DAC research peptide. GHRH analogue for growth hormone secretion, pulsatile GH release, and metabolic pathway studies.
